<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03045198</url>
  </required_header>
  <id_info>
    <org_study_id>Sylvia 253/12</org_study_id>
    <nct_id>NCT03045198</nct_id>
  </id_info>
  <brief_title>Effect of Azithromycin on Fatty Acids in CF</brief_title>
  <official_title>Effect of Azithromycin on Lipoproteins and Docosahexaenoic Acid in Patients With Cystic Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Childrens' Hospital (Zentrum für Kinderheilkunde des Universitätsklinikum Bonn)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Bonn</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Frankfurt</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Childrens' Hospital (Zentrum für Kinderheilkunde des Universitätsklinikum Bonn)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      In collaboration with Dr.Birgit Alteheld, Institute of Nutrional Sciences of the university
      of Bonn, Germany the following effect is explored: Effect of a 4 week therapy with AZT on
      synthesis of lipoproteins as well as Docosahexaen and other fatty acids in patients with
      Cystic Fibrosis (CF). Moreover proinflammatory cytokines in blood and sputum are of interest.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The macrolide azithromycin (AZT) is recommended by Flume in the CF pulmonary Guidelines for
      long-term treatment of patients with CF chronically colonized with Pseudomonas aeruginosa due
      to its immunomodulating properties . AZT causes a significant reduction of the
      proinflammatory cytokine Lipopolysaccharid binding protein (LBP) according to Steinkamp and
      Schmitt-Grohé. There is an inverse correlation between LBP and lung function. Moreover
      Schmitt-Grohé and coworkers provided evidence of a positive correlation between the
      lipoprotein HDL and lung function. Ribeiro and coworkers found an increased expression of
      Lipid/Cholesterol genes of primary human airway epithelial cultures after treatment with AZT.
      Freedman and coworkers were able to show decreased levels of Docosahexaen acid in CF
      patients.

      The aim of this study is to explore the impact of a 4 week trial of AZT on lipoprotein and
      fatty acids (docosahexaen acid etc.) synthesis.

      Delta F508 homozygous patients receive AZT (10 mg/kg body weight resp. max 500 mg) every
      Monday, Wednesday and Friday for 4 weeks. 20 patients (age 10-60 years) will be recruited.
      Fatty acids (blood), cytokines (whole blood and induced sputum) and clinical parameters are
      assessed before and 4 weeks after AZT treatment.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>CF patients receive for 4 weeks Azithromycin. Study measures are assessed before and after 4 weeks</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Lipoproteins in Serum (after overnight fast)</measure>
    <time_frame>Day 0 (before azithromycin), Day 28 (day 28 of azithromycin treatment)</time_frame>
    <description>VLDL,LDL,HDL, Cholesterin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Fatty acids in EDTA-Plasma and erythrocyte membranes (after overnight fast)</measure>
    <time_frame>Day 0 (before azithromycin), Day 28 (day 28 of azithromycin treatment)</time_frame>
    <description>linol acid, arachidon acid, Alpha linolen acid, eicosapentaen acid, Docoshexaen acidsdocosahexaen acid</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cytokines in induced sputum and whole blood</measure>
    <time_frame>Day 0 (before azithromycin), Day 28 (day 28 of azithromycin treatment)</time_frame>
    <description>Lipopolysaccharid binding Protein (LBP), interleukin-8 (IL-8) und Tumor necrosis factor Alpha (TNF Alpha)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICAM1 (Serum)</measure>
    <time_frame>Day 0 (before azithromycin), Day 28 (day 28 of azithromycin treatment)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Matrixmetalloprotease 9 (Serum)</measure>
    <time_frame>Day 0 (before azithromycin), Day 28 (day 28 of azithromycin treatment)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>WBC + CRP, IgE, RAST Aspergillus fum, ECP (Serum), Carotin, Vitamin E</measure>
    <time_frame>Day 0 (before azithromycin), Day 28 (day 28 of azithromycin treatment)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Shwachman-Score</measure>
    <time_frame>Day 0</time_frame>
    <description>Clinical score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body weight, length</measure>
    <time_frame>Day 0 (before azithromycin), Day 28 (day 28 of azithromycin treatment)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lung function test</measure>
    <time_frame>Day 0 (before azithromycin), Day 28 (day 28 of azithromycin treatment)</time_frame>
    <description>VC, FEV1, MEF 25</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nutrition protocol</measure>
    <time_frame>For 7 days before day 0 and day 28</time_frame>
    <description>Evaluation of Food intake and calculation of fat composition, Protein etc.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resolvins in EDTA plasma</measure>
    <time_frame>Day 0 (before azithromycin), Day 28 (day 28 of azithromycin treatment)</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>Azithromycin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oral Azithromycin 10 mg/kg Body weight, max. 500 mg every Monday, Wednesday and Friday for 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azithromycin</intervention_name>
    <arm_group_label>Azithromycin</arm_group_label>
    <other_name>Zithromax</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Delta 508 homozygous and regularly visiting the CF outpatient clinic Bonn

        Exclusion Criteria:

          -  clinical or laboratory signs (CRP &gt; 20 mg/L) of an exacerbation,

          -  treatment with systemic steroids 14 days preceeding this trial

          -  elevated liver function tests (&gt; twice normal range)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sabina Schmitt-Grohé, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Children's Hospital</affiliation>
  </overall_official>
  <reference>
    <citation>Freedman SD, Blanco PG, Zaman MM, Shea JC, Ollero M, Hopper IK, Weed DA, Gelrud A, Regan MM, Laposata M, Alvarez JG, O'Sullivan BP. Association of cystic fibrosis with abnormalities in fatty acid metabolism. N Engl J Med. 2004 Feb 5;350(6):560-9.</citation>
    <PMID>14762183</PMID>
  </reference>
  <reference>
    <citation>Steinkamp G, Schmitt-Grohe S, Döring G, Staab D, Pfründer D, Beck G, Schubert R, Zielen S. Once-weekly azithromycin in cystic fibrosis with chronic Pseudomonas aeruginosa infection. Respir Med. 2008 Nov;102(11):1643-53. doi: 10.1016/j.rmed.2008.03.009. Epub 2008 Aug 12.</citation>
    <PMID>18701270</PMID>
  </reference>
  <reference>
    <citation>Schmitt-Grohé S, Hippe V, Igel M, von Bergmann K, Posselt HG, Krahl A, Smaczny C, Wagner TO, Nikolazik W, Schubert R, Lentze MJ, Zielen S. Lipopolysaccharide binding protein, cytokine production in whole blood, and lipoproteins in cystic fibrosis. Pediatr Res. 2005 Nov;58(5):903-7. Epub 2005 Sep 23.</citation>
    <PMID>16183806</PMID>
  </reference>
  <reference>
    <citation>Flume PA, O'Sullivan BP, Robinson KA, Goss CH, Mogayzel PJ Jr, Willey-Courand DB, Bujan J, Finder J, Lester M, Quittell L, Rosenblatt R, Vender RL, Hazle L, Sabadosa K, Marshall B; Cystic Fibrosis Foundation, Pulmonary Therapies Committee. Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am J Respir Crit Care Med. 2007 Nov 15;176(10):957-69. Epub 2007 Aug 29.</citation>
    <PMID>17761616</PMID>
  </reference>
  <reference>
    <citation>Ribeiro CM, Hurd H, Wu Y, Martino ME, Jones L, Brighton B, Boucher RC, O'Neal WK. Azithromycin treatment alters gene expression in inflammatory, lipid metabolism, and cell cycle pathways in well-differentiated human airway epithelia. PLoS One. 2009 Jun 5;4(6):e5806. doi: 10.1371/journal.pone.0005806.</citation>
    <PMID>19503797</PMID>
  </reference>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 2, 2017</study_first_submitted>
  <study_first_submitted_qc>February 2, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 7, 2017</study_first_posted>
  <last_update_submitted>April 5, 2017</last_update_submitted>
  <last_update_submitted_qc>April 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Childrens' Hospital (Zentrum für Kinderheilkunde des Universitätsklinikum Bonn)</investigator_affiliation>
    <investigator_full_name>Sabina Schmitt-Grohe</investigator_full_name>
    <investigator_title>PD Dr Sabina Schmitt-Grohé</investigator_title>
  </responsible_party>
  <keyword>cystic fibrosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

